http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Diagnosis of Cardiac Metastasis from Endometrial Cancer by F-18 FDG-PET/CT
T. Liu,S. Khan,S. Behr,C. Mari Aparici 대한핵의학회 2014 핵의학 분자영상 Vol.48 No.3
We report a case of a 59-year-old woman with rightventricular metastasis of undifferentiated endometrial cancer. Cardiac metastasis from endometrial cancer is a very rarefinding. The case demonstrates that undifferentiated endometrialcancer is capable of metastasizing, presumably through ahematogenous route, to unexpected distant organs. Theseunexpected sites should not be undermined in the restagingand surveillance of these patients.
Development of a 60 Hz Power Standard Using SNS Programmable Josephson Voltage Standards
Burroughs, C.J.,Benz, S.P.,Dresselhaus, P.D.,Waltrip, B.C.,Nelson, T.L.,Yonuk Chong,Williams, J.M.,Henderson, D.,Patel, P.,Palafox, L.,Behr, R. Institute of Electrical and Electronics Engineers 2007 IEEE transactions on instrumentation and measureme Vol.56 No.2
<P>We are implementing a new standard for 60 Hz power measurements based on precision sinusoidal reference voltages from two independent programmable Josephson voltage standards (PJVS): one for voltage and one for current. The National Institute of Standards and Technology PJVS systems use series arrays of Josephson junctions to produce accurate quantum-based DC voltages. Using stepwise-approximation synthesis, the PJVS systems produce sinewaves with precisely calculable RMS voltage and spectral content. We present measurements and calculations that elucidate the sources of error in the RMS voltage that are intrinsic to the digital-synthesis technique and that are due to the finite rise times and transients that occur when switching between the discrete voltages. Our goal is to reduce all error sources and uncertainty contributions from the PJVS synthesized waveforms to a few parts in 10 <SUP>7</SUP> so that the overall uncertainty in the AC-power standard is a few parts in 10<SUP>6</SUP></P>
Brock, G.,Heiselman, D.,Maggi, M.,Kim, S.W.,Rodriguez Vallejo, J.M.,Behre, H.M.,McGettigan, J.,Dowsett, S.A.,Hayes, R.P.,Knorr, J.,Ni, X.,Kinchen, K. Williams and Wilkins Co 2016 The Journal of urology Vol.195 No.3
<P>Purpose: We determined the effect of testosterone solution 2% on total testosterone level and the 2 symptoms of hypogonadism, sex drive and energy level. Materials and Methods: This was a randomized, multicenter, double-blind, placebo controlled, 16-week study to compare the effect of testosterone and placebo on the proportion of men with a testosterone level within the normal range (300 to 1,050 ng/dl) upon treatment completion. We also assessed the impact of testosterone on sex drive and energy level measured using SAID (Sexual Arousal, Interest and Drive scale) and HED (Hypogonadism Energy Diary), respectively. A total of 715 males 18 years old or older with total testosterone less than 300 ng/dl and at least 1 symptom of testosterone deficiency (decreased energy and/or decreased sexual drive) were randomized to 60 mg topical testosterone solution 2% or placebo once daily. Results: Of study completers 73% in the testosterone vs 15% in the placebo group had a testosterone level within the normal range at study end point (p < 0.001). Participants assigned to testosterone showed greater baseline to end point improvement in SAID scores (low sex drive subset p < 0.001 vs placebo) and HED scores (low energy subset p = 0.02 vs placebo, not significant at prespecified p < 0.01). No major adverse cardiovascular or venous thrombotic events were reported in the testosterone group. The incidence of increased hematocrit was higher with testosterone vs placebo (p = 0.04). Conclusions: Once daily testosterone solution 2% for 12 weeks was efficacious in restoring normal testosterone levels and improving sexual drive in hypogonadal men. Improvement was also seen in energy levels on HED though not at the prespecified p < 0.01. No new safety signals were identified.</P>